Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
BriaCell Therapeutics ( (TSE:BCT) ) has provided an update.
BriaCell Therapeutics Corp. announced that it will conduct two virtual investor presentations on June 12 and June 26, 2025. These events, organized by Renmark Financial Communications Inc., invite stakeholders and investors to participate and gain insights into the company’s operations and future plans.
The most recent analyst rating on (TSE:BCT) stock is a Buy with a C$18.00 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.
Spark’s Take on TSE:BCT Stock
According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Neutral.
BriaCell Therapeutics has a challenging financial position with no revenue and consistent losses, heavily impacting its stock score. Despite this, recent corporate developments in cancer treatment provide some potential upside. Technical indicators are mixed, and valuation concerns persist with a negative P/E ratio. The company’s reliance on external financing is a notable risk.
To see Spark’s full report on TSE:BCT stock, click here.
More about BriaCell Therapeutics
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care.
Average Trading Volume: 16,230
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$26.41M
For detailed information about BCT stock, go to TipRanks’ Stock Analysis page.